Pharmaceuticals

XtalPi and EDDC Sign New Collaboration, Empowering Biomedical Innovation with Robotics and Large Language Models

SHENZHEN, China, Nov. 22, 2023 /PRNewswire/ -- Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC),Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboratio...

2023-11-22 09:00 3990

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients - ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors...

2023-11-21 20:15 3443

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and ATG-037 (oral CD73 inhibitor) have shown clinical responses in cancer patients with advanced diseases. * ATG-008 (dual mTORC1/2 inhibitor) continued showing strong cli...

2023-11-17 08:00 3003

TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug

Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that will be tested as part of Phase 2 trial The first participant has been dosed in this partially double-blind study to evaluate the safety and efficacy of what has the po...

2023-11-16 20:20 2076

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius(2696.HK)announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaledRMB407.8 million, attributed ...

2023-11-15 20:16 4346

RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Lat...

2023-11-15 16:35 2859

"Read Medicine Labels" - How to Safely Use Green Chiretta Against COVID-19

Chula Pharmaceutical Science points out the benefits and cautious use of green chiretta to better understand the drug, urging consumers to pay attention to"medicine labels" to choose and use green chiretta effectively and safely.   BANGKOK, Nov. 15, 2023 /PRNe...

2023-11-15 14:58 4694

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-11-14 21:30 1972

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 3684

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

MELBOURNE, Australia, Nov. 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based...

2023-11-14 06:33 2408

Rx-360 Releases Two New Publications in Support of the Pharmaceutical Industry and Patient Safety

PHILADELPHIA, Nov. 14, 2023 /PRNewswire/ -- Rx-360 is pleased to announce that the consortium membership led by key members of the Supplier Quality Working Group have released two new papers this week to help drive best practices in pharmaceutical supply chain integrity and patient safety. The t...

2023-11-14 03:00 3169

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...

2023-11-14 02:00 4501

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical c...

2023-11-13 20:20 2264

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to la...

2023-11-13 18:31 2108

Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam

Fundiin and Pharmacity have forged the first-ever Buy Now Pay Later (BNPL) partnership in the pharmacy retail sector, with Fundiin being the most popular BNPL provider inVietnam and Pharmacity emerging as the regional leading drugstore chain. HO CHI MINH CITY, Vietnam, Nov. 13, 2023 /PRNewswire/...

2023-11-13 14:58 4609

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...

2023-11-13 08:10 3907

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center inSouth Korea. Colorectal cancer (CRC) is o...

2023-11-13 08:00 4690

Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability

Company attributes B+ rating to progress related to its Human Rights Management Declaration, eco-friendly shipping box and the establishment of an internal ESG Committee SEOUL, South Korea, Nov. 10, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total so...

2023-11-10 20:00 4927

Shaping Global Policy: IFPA's Psoriatic Disease Response Index in the Western Pacific

STOCKHOLM, Nov. 10, 2023 /PRNewswire/ -- Psoriatic disease, recognized as a serious noncommunicable disease by the World Health Organization (WHO), impacts millions worldwide. A pioneering advocacy tool, the Psoriatic Disease Response Index, has emerged to facilitate a vital policy discussion, dr...

2023-11-10 19:18 5102

H2U Secures Strategic Investment from InnoTherapy as Recognition from Seoul Clinical Laboratories (SCL)

H2U platform enters the South Korean healthcare sector, driving AI-powered data analytics to expand their digital health offerings TAIPEI, Nov. 10, 2023 /PRNewswire/ -- H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving rec...

2023-11-10 17:48 4061
1 ... 91929394959697 ... 184